Despite COVID-19, we are operating at full capacity and all project work is operating as usual.

Clinically predictive preclinical efficacy testing services at your disposal



OCTOBER 14, 2020

Pharmatest to attend 3rd Annual Advances in Immuno-Oncology US Congress

This week on Thursday October 15th our oncology experts will virtually travel and attend the 3rd Annual Advances in Immuno-Oncology USA Congress.

The Congress includes over 300 attendees with more than 40 presentations and case studies focussed on the latest innovations in Immuno-Oncology therapy development, patient stratification and clinical research.

Don’t miss our presentation by Dr. Mari Suominen “Preclinical evaluation of IO Therapy Response in Bone Metastases” on October 15th at 11am PDT.

Pharmatest representatives will also host two roundtable discussions. On the first day of the meeting R&D Director Jenni Mäki-Jouppila will discuss about the topic “In vitro assays for studying the effects on tumor microenvironment” and on the second day of the meeting Research Director Mari Suominen will be moderating a roundtable discussion about “Experiences of Using CD34+ Humanized Mice”.

Please also visit our virtual booth to discuss about your oncology research!

Pharmatest’s agenda during the meeting:

October 15th

9:00am PDT

Live Booth Meeting: "Meet Pharmatest Services" by Jukka Rissanen, PhD, CEO

10am PDT 

Roundtable Discussion Titled: "In vitro assays for studying the effects on tumor microenvironment" by Jenni Mäki-Jouppila, PhD, R&D Director

11am PDT

Solution Provider Presentation: Evaluating IO Therapy Response In Bone Metastases by Mari Suominen, PhD, Research Director

12:00PDT

Live Booth Meeting: Q&A for poster "T Cell Killing Assay for Analyzing the Effects of Immunotherapies In Vitro" by Jenni Mäki-Jouppila, PhD, R&D Director

 

October 16th

9am PDT

Roundtable Discussion: "Experiences of Using CD34+ Humanized Mice" by Mari Suominen, PhD, Research Director

10am PDT

Live Booth Meeting: "Meet Pharmatest Services - Why to study bone in the context of immuno-oncology" by Jenni Mäki-Jouppila, PhD, R&D Director